J. Waters

发表

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial

D. Cunningham, A. Maraveyas, J. Bridgewater, 2018, British Journal of Cancer.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

A. Wotherspoon, D. Cunningham, D. Ferry, 2013, The Lancet. Oncology.

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

D. Cunningham, P. Clarke, F. Raynaud, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

D. Cunningham, A. Maraveyas, J. Bridgewater, 2015, The Lancet. Oncology.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

A. Horwich, A. Norman, D. Catovsky, 2005, British Journal of Cancer.

Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients

A. Norman, A. Wotherspoon, D. Cunningham, 2003, British Journal of Cancer.

Palliative treatments for patients with inoperable gastroesophageal cancers.

S. Popat, M. Hill, J. Waters, 2006, International journal of palliative nursing.

Management of anemia in patients receiving chemotherapy.

M. O'Brien, J. Waters, S. Ashley, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine and streptozocin +/- cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial.

T. Meyer, D. Talbot, D. Cunningham, 2016 .

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) che

A. Maraveyas, J. Bridgewater, P. Ross, 2019, Journal of Clinical Oncology.

A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).

A. Wotherspoon, D. Cunningham, D. Ferry, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of second-line chemotherapy for biliary tract cancer.

D. Cunningham, J. Bridgewater, D. Palmer, 2013, European journal of cancer.

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

B. Monk, A. Oza, R. Wenham, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins

D. Cunningham, W. Allum, J. Lagergren, 2021, Acta oncologica.

Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma.

D. Smith, D. Cunningham, W. Allum, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.

W. Ryder, A. Maraveyas, J. Bridgewater, 2021, The Lancet. Oncology.

OC-02 Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

A. Maraveyas, E. Gardiner, G. Bozas, 2010 .

6503 Gemcitabine with or without prophylactic weight-adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)

A. Maraveyas, E. Gardiner, K. Wedgwood, 2009 .

REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.

D. Smith, A. Wotherspoon, D. Cunningham, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

W. Ryder, A. Maraveyas, J. Bridgewater, 2021, The Lancet. Oncology.

Human Bcl-2 antisense therapy for lymphomas.

D. Cunningham, F. Cotter, J. Waters, 1999, Biochimica et biophysica acta.

The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE)

M. O'Brien, J. Waters, 2002, British Journal of Cancer.

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

J. Reis-Filho, D. Smith, M. Band, 2013, European journal of cancer.

Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

T. Eisen, I. Smith, P. Ross, 2004, British Journal of Cancer.

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

A. Norman, D. Cunningham, P. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Rare Case of Intravascular Lymphoma Diagnosed on Bone Marrow Trephine

J. Schofield, J. Waters, N. Maisey, 2003, Leukemia & lymphoma.

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer

A. Norman, D. Cunningham, I. Chau, 2001, British Journal of Cancer.

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.

D. Smith, D. Cunningham, W. Allum, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

A. Maraveyas, C. Ettelaie, E. Gardiner, 2012, European journal of cancer.

A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.

A. Padhani, A. Norman, D. Tait, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma

H. Grabsch, D. Alderson, A. Wotherspoon, 2019, JAMA oncology.

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

T. Hickish, A. Norman, M. Nicolson, 1999, British Journal of Cancer.

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

L. Assersohn, A. Norman, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

H. Grabsch, S. Grumett, P. Hall, 2021, JAMA oncology.

The changing face of chemotherapy in colorectal cancer

D. Cunningham, J. Waters, 2001, British Journal of Cancer.

A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.

T. Meyer, M. Peeters, J. Valle, 2010, European journal of cancer.

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.

H. Grabsch, S. Grumett, P. Hall, 2019, Journal of Clinical Oncology.

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

A. Norman, D. Cunningham, P. Ross, 2004, British Journal of Cancer.

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

M. Gore, R. A’Hern, J. Waters, 2004, British Journal of Cancer.

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER 2-Positive Gastroesophageal Adenocarcinoma : A Randomized Phase 2 Clinical Trial

H. Grabsch, D. Alderson, W. Allum, 2019 .

Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial.

H. Grabsch, D. Alderson, W. Allum, 2019 .

New approaches to the treatment of gastro-intestinal cancer.

D. Cunningham, P. Ross, R. Popescu, 1997, Digestion.

Primary non-Hodgkin's lymphoma of the thyroid with bone marrow infiltration at presentation.

J. Waters, A. el-Sharkawi, S. al-Ismael, 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

A. Wotherspoon, D. Cunningham, D. Ferry, 2013, The Lancet. Oncology.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British

A. Maraveyas, J. Bridgewater, C. Dive, 2018 .

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

A. Horwich, A. Norman, D. Catovsky, 2005, British Journal of Cancer.